Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Intravenous Therapy in Patients With Prosthetic Joint Infections

Next Previous
X
Search
Trial Profile

Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Intravenous Therapy in Patients With Prosthetic Joint Infections

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fusidic acid (Primary) ; Antibacterials; Antibacterials; Rifampicin
  • Indications Bone and joint infections; Staphylococcal infections
  • Focus Therapeutic Use
  • Sponsors Arrevus; Cempra Pharmaceuticals

    • Most Recent Events

    • 28 Sep 2016 Results of this trial, published in the Clinical Infectious Diseases journal.
    • 17 Apr 2015 According to a Cempra Pharmaceuticals media release, results from this trial will be presented at the 25th European Congress of Clinical Microbiology (ECCMID).
    • 09 Jun 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top